<DOC>
	<DOCNO>NCT03082573</DOCNO>
	<brief_summary>This study examine clinical response , cytokine expression joint image addition Acthar Gel . The hypothesis H.P . Acthar Gel safe effective treatment patient refractory rheumatoid arthritis ( RA ) different mechanism action steroid DMARDs .</brief_summary>
	<brief_title>Efficacy , Radiographic Laboratory Changes Refractory Rheumatoid Arthritis Patients Treated With H.P . Acthar Gel</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) systemic inflammatory disease cause premature mortality , disability compromise quality life industrialize developing world . The prevalence RA believe range 0.5-1.0 % general population . Over past half century , many study find mortality increase patient establish RA comparison general population . Despite available treatment option RA , patient still disease refractory treatment achieve remission . H.P . Acthar gel ( adrenocorticotropic hormone gel ) receive FDA approval treatment variety disease , include RA 1952 . The propose efficacy H.P . Acthar gel attribute ability induce production endogenous steroid bind melanocortin receptor lymphocytes cell modulate immunologic response . The present study examine clinical response , cytokine production joint image addition H.P . Acthar gel confirm efficacy , confirm different mechanism action comparison steroid DMARDs look post treatment change cytokine expression .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Patients diagnosis RA incomplete failure treatment describe either A B A : Failure achieve remission low disease activity within 3 6 month treatment combination methotrexate DMARDs therapy biologic DMARD maximally tolerate dos within usual therapeutic range . B A requirement , addition DMARDs biologic DMARDs , chronic glucocorticoid therapy dose great 5 7.5 mg/day prednisone equivalent achieve maintain remission low disease activity 3 6 month treatment . 2 . Fluent read write English language . 3 . ≥ 21 year age time participation . 1 . Pregnancy 2 . Presence contraindication treatment H.P . Acthar gel include limited known history scleroderma , osteoporosis , systemic fungal infection , ocular Herpes Simplex , recent administration live live attenuate vaccine ( prior 6 month ) , recent surgery ( prior 6 month ) , history presence peptic ulcer , primary adrenocortical insufficiency , adrenal cortical hyperfunction ; congestive heart failure ( defined New York Hear Association Functional Class I IV , uncontrolled hypertension . 3 . Previous use ACTH preparation treatment nephrotic syndrome ( include limit H.P . Acthar gel Synacthen® ) . 4 . Previous history sensitivity ACTH preparation ( include limit H.P . Acthar gel Synacthen® ) . 5 . Previous history sensitivity porcine protein product .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>